GENE REPLACEMENT OF DEFECTIVE BETA GLOBIN GENES
Award amount
$98,770Program and phase
SBIR · Phase IAward year
1997Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Morphogenesis, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- D638ZQHJJ9M1
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S.
- NOVEL IMMUNO POLYUMER DEVICE FOR CD34+ CELL ISOLATION
Research funding history
3 SBIR/STTR records share this UEI (1997–2021). Reported award amounts total $598,770. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services